Phase 3 N=471 Stimulant Abuser Groups to Engage in 12-Step
Drug Abuse
Primary: Days of Stimulant Use — 2.35; 2.13 days of stimulant use — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=613 A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease
Alzheimer's Disease
Primary: Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS/ADL) Inventory Change From Baseline — -1.72; -2.40; -2.78; -4.52 units on a scale — p=0.03
Phase 3 N=25,673 Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE
Cardiovascular Disease · Peripheral Arterial Disease · Diabetes Mellitus
Primary: Major Vascular Event — 1696; 1758 participants
Phase 3 N=351 CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)
Lymphocytic Leukemia, Chronic
Primary: Progression-free Survival (PFS) — 16.5; 11.1 Months — p=<0.0001
Phase 3 N=602 Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
Breast Neoplasms · Osteoporosis
Primary: Percent Change From Baseline in Lumbar Spine (L1-L4) Bone Mineral Density (BMD) — 1.955; -2.325 Percentage of BMD
Phase 3 N=744 A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD
Pulmonary Disease, Chronic Obstructive
Primary: Mean Change From Baseline in Clinic Visit Pre-dose Trough FEV1 at Day 169 — -0.027; 0.113; 0.152; 0.167 Liters — p=<0.001
Phase 3 N=95 An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease
Gaucher Disease, Type 1
Primary: Overall Summary of Treatment Emergent Adverse Events — 3; 1; 3; 38 Participants
Phase 3 N=40 Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility
Healthy
Primary: Gastric Volume — 262; 718 mL — p=<0.0001
Phase 3 N=126 Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above
Influenza
Primary: Percentages of Subjects With Seroconversion or Significant Increase in HI Titer Against Each of Three Vaccine Strains After One Vaccination of TIVc — 73; 58; 67; 45…
Phase 3 N=99 Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures
Partial Onset Seizures
Primary: Percent Change in Partial Onset Seizure Frequency Per 28 Days From Baseline to the Double-blind Phase, by Treatment Group — -2.85; 14.82 percentage change per 28 days
Phase 3 N=106 A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy
Hepatitis C, Chronic
Primary: The Percentage of Participants With a Sustained Virologic Response at the End of Treatment (EOT) and 12 Weeks After the Last Dose of Treatment (SVR12) — 52.8; 35.8…
Phase 3 N=304 Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling
Japanese Encephalitis
Primary: Primary: 1. Geometric Mean Titers (GMT) at Day 56 — 100.1; 84.7; 68.1 Geometric Mean Titer - Estimate
Phase 3 N=639 Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51
Japanese Encephalitis
Primary: GMT for Anti-JEV Neutralizing Antibody — 160.71; 272.24; 127.56 GMT
Phase 3 N=20 Dipeptidyl Peptidase-4 Inhibition and Immune Function in HIV
Diabetes · Insulin Resistance
Primary: CD4+ T-cell Count — 602; 648; 689; 750 cells/µL — p=>0.05
Phase 3 N=2,954 Novartis Vaccine and Diagnostics Carriage Trial
N. Meningitidis Carriage
Primary: Percentages of Subjects With Carriage of Virulent Sequence Types (ST) of Neisseria Meningitidis Group B, One Month After Completion of rMenB+OMV NZ Vaccination — 8; 7…